Clinical trial for the evaluation of efficacy and safety of NVP1703 on allergic rhinitis

VP Healthcare0 个研究点目标入组 80 人开始时间: 待定最近更新: 2023年8月1日

试验速览

暂无简介。

•Those who agreed to attend the protocol with the permission from one of their parent.
•Children who aged from 6 to <19 years.
•Children who show allergic rhinitis-compatible symptoms for more than 2 consecutive years.
•Children who gets more than 2 points of nasal symptoms during the run-in (from VIsit 1 to visit 2) periods.
•Children who did not take allergic drugs to relieve the nasal symptoms during the run-in period.

•Those who are taking medicine that might affect the allergic rhinitis control.
•Those who took the systemic steroid, nasal cromolyn, and loratadine 2 weeks before the screening.
•Those who took probiotics-containing food consecutively (more than 4 times/ week).
•Those who are under a treatment of gastritis or gastric ulcer.
•Those who are under the asthma treatment
•Those who suffered a severe neurovascular diseases, cardiac diseases for the recent 6 months (for the stable subjects the investigater can approve the participitation)
•Those who sufferes from the psychiatric diseases (depression, schizophrenia, drug addiction, etc)
•Those who the PI reasoned inappropriate to take part in the study.
•Recent or current attendence to another clinical study

发起方

VP Healthcare